番茄社区app

Meeting Coverage >

ASCO

Trial Results Spark Talk of Curing More Metastatic Cervical Cancers

Adding pembrolizumab to standard care extends overall survival by a year

P53 Antagonist Shows Early Activity in Advanced Liposarcoma

ASCO roundup: ADC targeting CD46 slows mCRPC, molecule stabilizes effects of "hot spot" mutation

Intensified Regimen for Metastatic CRC Fails to Improve Outcomes

Combination of modified FOLFOXIRI/panitumumab also caused greater toxicity, study showed

A Better Way to Irradiate Lethal CNS Metastases?

Randomized trial makes case for proton craniospinal irradiation for leptomeningeal spread

First-Line Anti-EGFR Extends OS in Left-Sided Colorectal Cancer

"A win for a highly selected group of patients," says ASCO expert

PARP Inhibitor Picks Up a Win in Frontline Maintenance for Ovarian Cancer

Median PFS more than doubled with rucaparib after response to platinum-based chemotherapy

Forego Radiotherapy for Women With Low-Risk Luminal A Breast Cancer?

Study shows 5-year local recurrence rate of 2.3% with lumpectomy and endocrine therapy alone

Targeted Combo Topples Chemo in Pediatric Glioma With BRAF Mutations

ORR quadrupled, median PFS nearly tripled with dabrafenib plus trametinib in low-grade disease

Radiation Alone May Suffice for Some Nasopharyngeal Cancer

Chemotherapy adds little benefit in intermediate grade lesions

Novel Agent Lessens Mucositis in Head and Neck Cancers

IV infusion could allow more patients to complete treatment regimen

Tiragolumab Fails in Extensive-Stage Small Cell Lung Cancer

No change in survival when combined with atezolizumab and chemotherapy

Liquid Biopsy May Save Colon Cancer Patients From Chemo

Circulating tumor DNA could determine who needs more therapy

Endocrine Switch Plus Ribociclib Active in Post-CDK4/6 Inhibitor Progression

First randomized support for strategy in progressive metastatic HR+/HER2- breast cancer

Myeloma Trial Supports 'Personalized Approach' to Upfront Transplant

DETERMINATION confirms benefit in triple-therapy setting, but suggests timing can be tailored

Complete Responses in 100% of dMMR Rectal Cancer With Neoadjuvant PD-1 Inhibition

Chemo, RT, surgery avoided in short-term follow-up but study population was small

Trastuzumab Deruxtecan Ushers in New Treatment Era for HER2-Low Breast Cancer

DESTINY-Breast04 extends agent's benefits to historically tough-to-treat disease

Will High-Dose Ifosfamide Become the Go-To Therapy in Recurrent Ewing Sarcoma?

Data from European rEECur trial "are potentially practice changing," expert says

Third-Line BTK Inhibitor Combo Doubles PFS in Follicular Lymphoma

Significantly more responses, CRs with zanubrutinib-obinutuzumab versus anti-CD20 drug alone

Capivasertib-Fulvestrant Combo Ups Survival in ER+/HER2- Metastatic Breast Cancer

But benefit seems to be predominantly in patients with PI3K/AKT/PTEN pathway alterations

Sacituzumab Govitecan Boosts PFS in Late-Line HR+/HER2- Metastatic Breast Cancer

"This may be something that really changes the lives of these women for the better," expert says

Immunotherapy Rechallenge in NSCLC Yields Overall Survival Boost

Phase II trial sees "synergistic benefit" with checkpoint blockade and anti-angiogenesis

IL-15 Agonist Impresses in Non-Muscle Invasive Bladder Cancer

High response rate, 99%-100% cancer-specific survival at 2 years

Brentuximab Vedotin-Chemo Boosts EFS in High-Risk Pediatric Hodgkin Lymphoma

Combo regimen offers "a new standard for front-line therapy," researcher says

KRAS Inhibitor Shrinks Tumors in Over 40% of NSCLC Patients

Median survival surpasses 1 year in heavily pretreated population

Add-On Ibrutinib Boosts PFS in Untreated, Older Mantle-Cell Lymphoma Patients

BTK inhibitor plus chemoimmunotherapy increased progression-free survival by over 2 years

Survival Bump With EGFR Inhibitor for KRAS Wild-Type Pancreatic Cancer

But generalizability of "notable" Chinese study questioned

Increased Public Assistance Tied to Better Cancer Survival in Black Patients

Disparity in 5-year OS declined by more than 40% with each 10% boost in public welfare spending

Cancer Outcome Disparities Not Fully Explained by Race, Socioeconomic Factors

Worse 5-year OS in Hispanic children with high-risk neuroblastoma in adjusted analysis

Black Patients Often Never Given a Chance to Join Breast Cancer Trials

But survey finds several actionable findings that could boost enrollment

COVID Increased Use of Telemedicine for Cancer Care, Though Not Equitably

Black, uninsured, non-urban patients less likely to use these services

Tweaking Maintenance Options in Metastatic CRC

Two studies move the needle, but no major breakthroughs

Bispecific Antibody Active in NRG1-Positive Pancreatic Cancer

Zenocutuzumab turns in promising results in early-phase trial involving multiple solid tumors

Promising Early Data for Bladder-Sparing Cancer Treatment

Bladder-intact DFS at 1 year nears 90% for muscle-invasive bladder cancer

TRK Inhibitor Proves Beneficial in Primary CNS Tumors

One-year OS rate with larotrectinib was 85%

New Standard for Metastatic Castration-Sensitive Prostate Cancer?

Triplet regimen reduced the risk for radiographic progression or death, but OS data await

'Important' Advance in Tough-to-Treat Thyroid Cancer

Targeted therapy cabozantinib may represent a new standard in heavily pretreated patients

More Support for Gene Assay to Guide Breast Cancer Treatment

More nuanced data on treatment de-escalation, extended endocrine therapy

Another CAR-T Impresses in Follicular Lymphoma

Complete responses in 66% of patients with relapsed or refractory disease

BPAs Cut Fracture Risk in Metastatic Prostate Cancer

Those receiving enzalutamide with and without radium-223 saw benefits in updated safety analysis

Acalabrutinib Offers Less Wear and Tear on the Heart in CLL Patients

BTK inhibitor had less cardiotoxicity than ibrutinib, but similar efficacy

2